Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Anvumetostat Combination Therapy in MTAP-deleted Pancreatic Ductal Adenocarcinoma
jRCT2031240376Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of anvumetostat in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Amgen. Primary endpoints: Number of participants experiencing dose-limiting toxicities (DLT), Number of participants experiencing treatment-emergent adverse events (TEAE) and 1 more. Started May 2024; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031240376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240376.